Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant
Clinical trial NCT03439046 · TERMINATED
Trial details
- NCT number
- NCT03439046
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-02-02
- Primary completion
- 2023-12-11
- Enrollment
- 287
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.